Abstract library

73 results for "Mare".
#829 On the Benign Side of Malignancy: How Neuroendocrine Tumors are Experienced by Patients and Their Family Carers
Introduction: Neuroendocrine tumors (NETs) are rare, slow-growing neoplasia with variable clinical presentations. Due to their non-specific symptoms and a lack of diagnostic tools, late diagnosis is common. There is little research relating to NETs as experienced by both patients and family carers.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Susanne Kall
#180 Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
Introduction: The role of anti-angiogenic agents in GEP-NETS remains to be established. CD105 (Endoglin) identifies the TGF-ß1 receptor which is expressed on endothelial cells involved in tumor angiogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Carlos A. S. Soares
#362 Succinate Dehydrogenase (SDH) Complex Expression in Pancreatic Endocrine Tumours (PETs)
Introduction: Absence of SDH subunit D (SDHD) mutations were reported by Perren et al (Oncogene 2002) but loss of heterozigosity (LOH) was described in 29% of the PETs. Since SDHD gene may depict a form of genomic imprinting in neuroendocrine (NE) tissue, the reported LOH may drive activation of the hypoxia pathway. Taking advantage from the immunohistochemical (IHC) method for genetic triage we may deduce the mutational status of SDH subunits (A, B, C and D) based on IHC SDHB expression. These subunits are striking candidates as they are mutated in other NE neoplasias.
Conference:
Category: Basic
Presenting Author: Mr João Vinagre
Authors: Vinagre J, Preto J, Soares P, Lopes J M, ...
Keywords: PETs SDH LOH
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês
Authors: Soares M, Inês M, Contente M, ...
#699 Ethanol Ablation in an 81-Year-Old Patient with Pancreatic Neuroendocrine Tumor (Islet Cell Tumor) and Severe Hypoglycemia – A Case Study.
Introduction: The key clinical problem in patients with islet cell tumors are persistent hypoglycemia episodes, which are particularly dangerous in the elderly since neuroglycopenia may be the cause of stroke.
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: Elżbieta Andrysiak-Mamos
#782 Appendix Well-Differentiated Neuroendocrine Tumors (A-WDNETs) at a Large Tertiary Center: Clinical-Pathological Features and Long-Term Follow-Up Evaluation
Introduction: A-WDNETs comprise 32-57% of appendix tumors, diagnosed incidentally in 0.3-0.9% appendectomies (AP). Overall survival is good, but malignant behavior remains controversial.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. John Preto
#1461 Whole Exome Sequencing of Three Families with Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (siNETs) are the most prevalent small intestine neoplasms. However, familial siNETs are rarely described.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Matthias Beyens
#1629 To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis
Introduction: Somatostatin analogs (SSAs) or watchful-waiting are recommended for unresectable, well- or moderately-differentiated non-functioning GEP-NET.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Dima Samaha
#1689 The Prognostic Value of the Expression of Cytokeratin 7 and 19 in Lungs and Pancreas Neuroendocrine Tumors
Introduction: The expression of cytokeratins (CK) 7,19 rarely occurs in the low grade neuroendocrine tumors (NET) of lung and pancreas. It is known that part of the low grade typical (TC) and atypical (ATС) carcinoids of lung and pancreas (pNET-G1,G2) can progress quickly and to metastasize. It is important to distinguish NET with a less differentiated cells immunophentype.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Iya A Voronkova
#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Taymeyah Al-Toubah
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, ...